Bookmark

Add to MyYahoo RSS

Isis Pharmaceuticals News

News on Isis Pharmaceuticals (Ticker: ISIS) continually updated from thousands of sources around the net.

Wednesday | AmericanBankingNews.com

ISIS Pharmaceuticals Given Average Rating of "Hold" by Analysts

Shares of ISIS Pharmaceuticals have earned a consensus rating of "Hold" from the eleven ratings firms that are covering the company, Analyst Ratings Network.com reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Apr 15, 2014

Seeking Alpha

Is Biogen A Value Stock Yet?

Biogen Idec may be headquartered in Cambridge, Massachusetts, but it still has many ties to my hometown of San Diego.

Comment?

Related Topix: Biotech, Biogen Idec, Cambridge, MA, Science / Technology, Medicine, Healthcare Industry, Hemophilia, Health, Multiple Sclerosis

Tue Apr 08, 2014

Sys-Con Media

Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer,...

Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. , Endo International PLC , ISIS Pharmaceuticals, Inc. , IDEXX Laboratories, Inc. , and Novo ... (more)

Comment?

Related Topix: Biotech, Medicine, IDEXX Laboratories, Healthcare Industry, Endo Pharmaceuticals Holdings, Salix Pharmaceuticals, Novo Nordisk AS

Sat Apr 05, 2014

AmericanBankingNews.com

ISIS Pharmaceuticals CEO Stanley T. Crooke Sells 8,800 Shares

ISIS Pharmaceuticals CEO Stanley T. Crooke sold 8,800 shares of the stock on the open market in a transaction dated Wednesday, April 2nd.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Apr 02, 2014

BioResearch Online

Isis Reports Positive Phase 2 Study Results For Antisense Drug

Isis Pharmaceuticals Inc. announced positive final results from the Phase II study evaluating its antisense drug ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Diabetes

Tue Apr 01, 2014

PR-inside.com

"Isis Pharmaceuticals, Inc. - Strategy and SWOT Report" now available at Fast Market Research

Isis Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Carlsbad, CA

Hispanic Business

Thomson Reuters Announces Nominations for Top Pharma Deals of the Year

The awards -- to be determined by public vote -- will be presented , at Allicense [ http://www.allicense.com/ ], a prominent event connecting business development, licensing and M&A professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Mar 31, 2014

Applied Clinical Trials

Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With...

In this study, patients treated with ISIS-APOCIIIRx achieved average reductions of up to 71 percent in apolipoprotein C-III and up to 64 percent in triglycerides, and average increases of up to 52 percent in high-density lipoprotein cholesterol , the 'good' cholesterol.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Sat Mar 29, 2014

PR-inside.com

"Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014" now available at Fast Market Research

This report provides information on the therapeutic development for Spinal Muscular Atrophy , complete with latest updates, and special features on late-stage and discontinued projects.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Mar 28, 2014

Sys-Con Media

Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma

The losses were broad based as nine out of 10 sectors ended the session in negative.

Comment?

Related Topix: Biotech, Medicine, Array BioPharma, Healthcare Industry, Startups, Pharmacyclics, Financial Markets

Mon Mar 24, 2014

Benzinga

EARLIER: Isis Announces Antisense Targeting of HBV Produces...

Isis Pharmaceuticals, Inc. announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Scripps Research Institute, Technical Services, Essex County, England, World News, United Kingdom, Greater London County, England, Liver Cancer, Pharmacology

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••